New CTC trial results presented at ASCO
New CTC trial results, including a simple skin cancer preventive, presented at American Society of Clinical Oncology meeting
Andrew Martin, CTC senior biostatistician, presented results of
the ONTRAC study at the meeting of the American Society of Clinical
Oncology (ASCO) in Chicago on Saturday, 30 May.
ONTRAC was a phase III trial showing that oral
nicotinamide significantly reduced the formation of new nonmelanoma
skin cancers compared with placebo in patients with severely
sun-damaged skin. It was a University of Sydney study led by Dr
Diona Damian from the Department of Dermatology.
This presentation was a highlight
of the meeting and its important results have been reported
The results of the CTC's trials, CABARET (advanced
glioblastoma, brain cancer) and INTEGRATE (oesophagogastric cancer)
were also announced at ASCO.
References to all CTC ASCO presentations follow. Full details of
each presentation are available from the search page here.
Bamias A, Dimopoulos MA, Zagouri F, Veillard AS, Kosse J,
Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M,
Floquet A, Lee C, Gebski V, Pujade-Lauraine E. Bevacizumab with or
after chemotherapy for platinum-resistant recurrent ovarian cancer:
exploratory analyses of the AURELIA trial.
Barbour A, O'Rourke N, Chandrasegaram MD, Chua YJ, Kench J,
Samra JS, Pavlakis N, Haghighi KS, Yip S, Fawcett J, Donoghoe M,
Walker K, Burge ME, Gananadha S, Harris M, Aghmesheh M, Joubert WL,
Gebski V, Simes J, Goldstein D. A multicenter, phase II trial of
preoperative gemcitabine and nab-paclitaxel for resectable pancreas
cancer: the AGITG GAP study.
Chan D, Goldstein D, Sjoquist KM, Pavlakis N. Antiangiogenic
agents in metastatic oesophago-gastric cancer: a systematic review
Chin V, Nagrial A, Chantrill L, Sjoquist K, O'Connor C, Pajic M,
Biankin A, Yip D. Targeted therapies in the treatment of advanced
pancreatic adenocarcinoma: a systematic review and meta-analysis of
randomized trials. Davis ID, Stockler MR, Martin AJ, Marchesin V,
Deignan O, McDermott R, Parulekar WR, North SA, Graham B, Long AP,
Roncolato FT, Yip S, Hague W, Dazo CC, X., Sweeney C. Randomised
phase 3 trial of enzalutamide in first line androgen deprivation
therapy for metastatic prostate cancer: the ANZUP ENZAMET trial
Duchesne GM, Bassett J, D'Este C, Frydenberg M, Ledwich L,
Millar JL, Milne RLS, R., Spry N, Stockler MR, Syme R, Turner S,
Tai KH, Woo H, TROG & Cancer Council Victoria. TROG 03.06 and
VCOG PR 01-03: The "timing of androgen deprivation therapy in
prostate cancer patients with a rising PSA (TOAD)" collaborative
randomised phase III trial.
Friedlander M, Stockler MR, O'Connell R, Joly F, Lanceley A,
Hilpert F, Okamoto A, Aotani E, Pignata S, Donnellan PP, Oza AM,
Avall-Lundqvist E, Berek JS, Sjoquist KM, Gillies K, Butow P, King
MT. Is it time to change the primary endpoint in clinical trials in
recurrent ovarian cancer?: Symptom burden and outcomes in patients
with platinum resistant/refractory and potentially platinum
sensitive recurrent ovarian cancer receiving ≥3 lines of
chemotherapy (≥3)-the Gynecologic Cancer Intergroup Symptom Benefit
Gibbs P, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Gebski V,
Van Buskirk M, Van Hazel G, SIRFLOX Study Group. SIRFLOX:
randomized phase III trial comparing first-line mFOLFOX6 ±
bevacizumab versus mFOLFOX6 + selective internal radiation therapy
± bevacizumab in patients with metastatic colorectal cancer.
Hovey EJ, Field KM, Rosenthal M, Nowak AK, Cher L, Wheeler H,
Barnes E, Phal P, Livingstone A, Sawkins K, Simes J, COGNO CABARET
Investigators. Continuing or ceasing bevacizumab at disease
progression: results from the CABARET study, a prospective
randomized phase II trial in patients with recurrent
Lee C, Davies LC, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C,
Nakagawa K, Throngprasert S, Fukuoka M, Gralla RJ, Gebski V, Mok T,
Yang JCH. The impact on overall survival of first-line gefitinib
and erlotinib and of clinical factors in advanced non-small cell
lung cancer with activating epidermal growth factor receptor
mutations based on meta-analysis of 1,231 patients enrolled in 6
major randomized trials.
Lee C, Gibbs E, ROncolato FT, Davies LC, Le Maignan C, Meier W,
Lanza MAA, Rosenberg P, Marchetti C, Vergote I, Witteveen P, Bamias
A, Serra S, Provencal J, De Rauglaudre G, Gebski V, Friedlander M,
Pujade-Lauraine E. Development and validation of a prognostic
nomogram to predict overall survival in platinum-resistant ovarian
cancer: An AURELIA substudy.
Martin AJ, Chen A, Choy B, Fernandez-Penas F, Halliday GM,
Dalziell R, McKenzie C, Scolyer RA, Dhillon HM, Vardy JL, St George
G, Chinniah N, Damian DL. Oral nicotinamide to reduce actinic
cancer: a phase 3 double-blind randomized controlled trial.
Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang YK, Bang
YJ, O'Callaghan CJ, tebbutt NC, Rha SY, Cho JY, Lipton LR, Burnell
MJ, Alcindor T, Strickland A, Kim JW, Yip S, SImes J, Zalcberg J,
Goldstein D. INTEGRATE: a randomized, phase II, double-blind,
placebo-controlled study of regorafenib in refractory advanced
oesophagogastric cancer: a study by the Australasian
Gastrointestinal Trials Group (AGITG)-final overall and subgroup
Roncolato F, O'Connell RL, Joly F, Lanceley A, Hilpert F,
Okamoto A, Aotani E, Pignata S, Donnellan PP, Oza AM,
Avall-Lundqvist E, Berek JS, Sjoquist KM, Gillies K, Butow P,
Stockler MR, King MT, Friedlander M. Baseline predictors of early
treatment failure in patients with platinum resistant/refractory
and potentially platinum sensitive (≥3) recurrent ovarian cancer
receiving ≥3 lines of chemotherapy: the Gynaecologic Cancer
Intergroup Symptom Benefit Study.
Sjoquist KM, Bokemeyer C, Renfro LA, Simes J, Tebbutt NC, S.J.
C, Adams R, Punt CJA, Cutsem EV, Douillard JY, Hecht R, Heinemann
V, Sougklakos I, Diaz-Rubio E, Porschen R, Meyers JP, Gonsalves WI,
Sargent DJ, De Gramont A, Zalcberg J. Calculators for overall
survival and progression-free survival in metastatic colorectal
cancer: construction from 19,678 ARCAD patients.
Trillsch F, Mahner S, Hilpert F, Davies LC, Garcia-Martinez E,
Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff
L, Sehouli J, Lee C, Gebski V, Pujade-Lauraine E. Prognostic and
predictive value of primary vs secondary platinum resistance for
bevacizumab treatment in platinum-resistant ovarian cancer in the
Williams SG, Davis ID, Sweeney C, Stockler MR, Martin AJ,
Marchesin V, Deignan O, McDermott R, Long AP, Roncolato FT, Yip S,
Hague W, Tu E, Coskinas X, Nguyen PL. Randomised phase 3 trial of
enzalutamide in androgen deprivation therapy with radiation therapy
for high risk, clinically localised prostate cancer: the ANZUP
ENZARAD trial (ANZUP 1303).
Zdenkowski N, Green M, Boyle FM, Kannourakis G, Gill PG, Bayliss
E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Gebski V,
Veillard AS, Davies LC, Thornton R, Fong A, Reaby LL, Forbes JF,
Australia and New Zealand Breast Cancer Trials Group. Final
analysis of a randomized comparison of letrozole vs observation as
late reintroduction of adjuvant endocrine therapy for
postmenopausal women with hormone receptor positive breast cancer
after completion of prior adjuvant endocrine therapy: ANZBCTG 0501
2 June 2015